Simplifying and optimising management of acute malnutrition in children aged 6 to 59 months: study protocol for a community-based individually randomised controlled trial in Kasaï, Democratic Republic of Congo. Issue 12 (2nd December 2020)

• Record Type: Journal Article
• Authors: Cazes, Cécile; Phelan, Kevin; Hubert, Victoire; Alitanou, Rodrigue; Boubacar, Harouna; Izie Bozama, Liévin; Tshibangu Sakubu, Gilbert; Beuscart, Aurélie; Yao, Cyrille; Gabillard, Delphine; Kinda, Moumouni; Augier, Augustin; Anglaret, Xavier; Shepherd, Susan; Becquet, Renaud
• Is Part Of: BMJ open. Volume 10:Issue 12(2020)
• Publication Date: 2020-12-02
• Subjects: nutrition -- public health -- clinical trials -- paediatric pathology -- community child health -- protocols and guidelines; Medicine -- Research -- Periodicals; 610.72
• DOI: 10.1136/bmjopen-2020-041213
• Languages: English
• ISSNs: 2044-6055

Abstract

Abstract : Introduction: Acute malnutrition (AM) is a continuum condition, arbitrarily divided into moderate and severe AM (SAM) categories, funded and managed in separate programmes under different protocols. Optimising acute MAlnutrition (OptiMA) treatment aims to simplify and optimise AM management by treating children with mid-upper arm circumference (MUAC) <125 mm or oedema with one product—ready-to-use therapeutic food—at a gradually tapered dose. Our main objective was to compare the OptiMA strategy with the standard nutritional protocol in children 6–59 months presenting with MUAC <125 mm or oedema without additional complications, as well as in children classified as uncomplicated SAM (ie, MUAC <115 mm or weight-for-height Z-score (WHZ) <−3 or with oedema). Methods and analysis: This study was a non-inferiority, individually randomised controlled clinical trial conducted at community level in the Democratic Republic of Congo. Children 6–59 months presenting with MUAC <125 mm or WHZ <−3 or with bipedal oedema and without medical complication were included after signed informed consent in outpatient health facilities. All participants were followed for 6 months. Success in both arms was defined at 6 months post inclusion as being alive, not acutely malnourished per the definition applied at inclusion and without an additional episode of AM throughout the 6-month observation period. Recovery among children with uncomplicated SAM was the main secondary outcome. For the primary objective, 890 participants were needed, and 480 children with SAM were needed for the main secondary objective. We will perform non-inferiority analyses in per-protocol and intention-to-treat basis for both outcomes. Ethics and dissemination: Ethics approvals were obtained from the National Health Ethics Committee of the Democratic Republic of Congo and from the Ethics Evaluation Committee of Inserm, the French National Institute for Health and Medical Research (Paris, France). We will submit results for publication to a peer-reviewed journal and disseminate findings in international and national conferences and meetings. Trial registration number: NCT03751475 . Registered 19 September 2018, https://clinicaltrials.gov/ct2/show/NCT03751475 .